Granulosa cell tumours of the ovary comprise approximately 3-5% of all ovarian neoplasms (Williams, 1985) . They are sometimes associated with secretion of oestrogens, and less commonly androgens and progestagens. These tumours often have a protracted history and can recur many years after excision of the original tumour. Treatment of metastatic tumour generally involves radiotherapy to achieve disease control at metastatic sites (Simmons & Sciarra, 1967) or chemotherapy (Camlibel & Caputo, 1983) . Extraabdominal spread is one of the factors associated with a poor prognosis (Fox et al., 1975 Camlibel and Caputo (1983 (Kurman et al., 1979; Galli et al., 1981; Meyer et al., 1982; Schwartz et al., 1983) . Kurman et al. (1979) were able to demonstrate progesterone receptors in six out of 11 granulosa cell tumours by immunohistochemical techniques. Galli et al. (1981), and Meyer et al. (1982) , also showed the presence of progesterone receptors in a total of three tumours studied, and suggested that therapy with progestagens may be effective in their treatment. Schwartz et al. (1983) were able to demonstrate progesterone receptors in two out of three tumours studied, and reported stabilisation of disease in one patient with progestagen therapy. Young et al. (1982) showed specific binding of tritiated MPA to a cytosolic progesterone receptor in a granulosa cell tumour of the ovary.
The cases reported here demonstrate that MPA can induce tumour regression in advanced cases of granulosa cell tumours that have become resistant to first-line combination chemotherapy. A point of interest was the possible doseresponse relationship noted in one of the patients, suggesting that dose escalation should be considered in patients not responding initially to MPA at a dose of 100 mg three times a day. MPA should be considered as a possible therapy in patients with granulosa cell tumours of the ovary after failure of first-line chemotherapy, or indeed as a potential first-line therapy in patients unsuitable for chemotherapy.
